Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

PURPOSE: T cells can be genetically modified to express an anti-CD19 chimeric antigen receptor (CAR). We assessed the safety and efficacy of administering autologous anti-CD19 CAR T cells to patients with advanced CD19(+) B-cell malignancies. PATIENTS AND METHODS: We treated 15 patients with advance...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Oncol
Egile Nagusiak: Kochenderfer, James N., Dudley, Mark E., Kassim, Sadik H., Somerville, Robert P.T., Carpenter, Robert O., Stetler-Stevenson, Maryalice, Yang, James C., Phan, Giao Q., Hughes, Marybeth S., Sherry, Richard M., Raffeld, Mark, Feldman, Steven, Lu, Lily, Li, Yong F., Ngo, Lien T., Goy, Andre, Feldman, Tatyana, Spaner, David E., Wang, Michael L., Chen, Clara C., Kranick, Sarah M., Nath, Avindra, Nathan, Debbie-Ann N., Morton, Kathleen E., Toomey, Mary Ann, Rosenberg, Steven A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2015
Gaiak:
ORIGINAL REPORTS
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4322257/
https://ncbi.nlm.nih.gov/pubmed/25154820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.56.2025
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak